RadNet (NASDAQ:RDNT – Get Free Report) posted its quarterly earnings results on Monday. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.08, FiscalAI reports. The business had revenue of $638.26 million for the quarter, compared to analyst estimates of $639.97 million. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%.
RadNet Stock Performance
Shares of NASDAQ:RDNT opened at $76.00 on Monday. The stock has a market capitalization of $5.98 billion, a price-to-earnings ratio of -281.47 and a beta of 1.42. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.48. The stock’s 50-day simple moving average is $72.57 and its two-hundred day simple moving average is $65.40. RadNet has a 52-week low of $50.82 and a 52-week high of $85.84.
Wall Street Analysts Forecast Growth
Several research firms recently commented on RDNT. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Zacks Research raised shares of RadNet from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 9th. Truist Financial boosted their price target on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research note on Wednesday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $90.00.
View Our Latest Analysis on RadNet
RadNet Company Profile
RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.
The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.
Read More
- Five stocks we like better than RadNet
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
